Long-Term Outcomes & Sustainability

    Evidence-based insights on maintaining your weight loss success, understanding long-term health impacts, and creating sustainable strategies for lasting results with GLP-1 medications.

    18 min

    Tirzepatide and Semaglutide: Long-Term Effects and Maintenance

    Understanding what happens long-term on GLP-1 medications, weight maintenance after stopping, and strategies for lasting success.

    Read article
    8 min

    Maintaining Weight Loss After Stopping GLP-1s

    Evidence-based strategies for sustaining your weight loss results after discontinuing semaglutide or tirzepatide therapy.

    Read article
    10 min

    Long-Term Health Effects of Semaglutide: 5-Year Data

    Comprehensive analysis of extended semaglutide use on cardiovascular health, metabolic markers, and overall wellbeing.

    Read article
    7 min

    Sustainability Strategies for GLP-1 Therapy

    Creating a sustainable long-term treatment plan with GLP-1 medications for lasting weight management success.

    Read article
    9 min

    Lifestyle Changes for Post-GLP-1 Success

    Building healthy habits during GLP-1 treatment to ensure continued success after medication discontinuation.

    Read article
    8 min

    Long-Term Metabolic Benefits of GLP-1 Medications

    Understanding how GLP-1 therapies create lasting improvements in insulin sensitivity, inflammation, and metabolic health.

    Read article
    6 min

    Managing Expectations for Long-Term GLP-1 Use

    Setting realistic goals and understanding what to expect from extended GLP-1 therapy for weight management.

    Read article
    14 min

    Weight Regain After Stopping GLP-1: Prevention Strategies

    Learn why weight regain occurs after stopping GLP-1 medications and discover evidence-based strategies to maintain your weight loss long-term.

    Read article
    11 min

    Overcoming GLP-1 Weight Loss Plateaus

    Practical strategies for breaking through weight loss stalls on semaglutide or tirzepatide and maximizing your results.

    Read article
    10 min

    Real-World GLP-1 Weight Loss Results: Clinical Studies

    Compare recent real-world tirzepatide and semaglutide outcomes from 2025 observational studies.

    Read article

    Ready to Start Your Weight Loss Journey?

    Get personalized GLP-1 treatment with ongoing support for long-term success. Our medical team helps you build sustainable habits for lasting results.

    Get Started Today

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    What are the long-term outcomes of GLP-1 weight-loss medication?

    Long-term GLP-1 outcomes are well-characterized for semaglutide and increasingly for tirzepatide. Sustained weight loss is achievable when treatment is continued — STEP 1 showed ~15% body-weight reduction at 68 weeks. STEP 4 showed that continued semaglutide maintained weight loss while discontinuation led to ~two-thirds of the lost weight being regained within 52 weeks. Cardiovascular benefit is established (SELECT trial: 20% reduction in major adverse cardiovascular events with semaglutide in overweight patients with prior CV disease). Renal protection in CKD patients with type 2 diabetes is established for semaglutide (FLOW trial). For tirzepatide, SURMOUNT-4 demonstrated maintained loss with continued therapy. The long-term picture: GLP-1 medications are most effective as ongoing therapy, not short courses.

    STEP 1: ~15% sustained loss at 68 weeks on continued semaglutide.
    SELECT: 20% reduction in major adverse cardiovascular events.
    STEP 4: ~2/3 of lost weight regained within 52 weeks of stopping.

    Key Takeaways

    • Long-term GLP-1 outcomes data: STEP 1 demonstrated sustained ~15% weight reduction at 68 weeks; STEP 4 showed continued weight loss when treatment was maintained vs partial regain when stopped.
    • Cardiovascular benefit (SELECT trial): semaglutide reduced major adverse cardiovascular events by 20% in overweight patients with prior cardiovascular disease.
    • Renal protection (FLOW trial): semaglutide slowed CKD progression in patients with type 2 diabetes and chronic kidney disease.
    • Weight regain after discontinuation is the dominant long-term concern; STEP 4 showed approximately two-thirds of weight loss was regained within 52 weeks of stopping.

    Medically Reviewed

    DMR

    Dr. Michael Rodriguez

    MD, FACP, Board Certified in Internal Medicine

    Internal Medicine & Weight Management

    Last reviewed: January 15, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Dr. Michael Rodriguez, MD, FACP, Board Certified in Internal Medicine

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    — Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    — Veronica LarimoreFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    4. Aronne LJ, et al. (2024). Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine / PubMed.Read StudyDOI: 10.1056/NEJMoa2307563
    6. Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine / PubMed.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    GLP-1 Medications

    Microdosing GLP-1 Medications

    Evidence-based guide on long-term GLP-1 use. Learn about weight regain data from STEP 1 extension trials, maintenance strategies, dose reduction, and when stopping may be appropriate.

    10 minRead More
    Retatrutide

    Retatrutide: Complete Guide

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    10 minRead More
    Comparisons

    Best Online Weight Loss Doctor 2026: Top Telehealth Providers

    Complete guide covering finding the best online weight loss doctors in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at u

    10 minRead More
    GLP-1 Medications

    How Retatrutide Works

    Retatrutide produced up to 24% weight loss in Phase 2 trials. See dose-response data, comparison with semaglutide and tirzepatide, timeline projections, and FDA approval outlook.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started